Biogen's troubled Aduhelm hit with CMS slapdown—now what? | Fierce Pharma
Biogen's troubled Aduhelm hit with CMS slapdown—now what?
Without meaningful access for more patients, the negative Medicare policy “likely spells the end for Aduhelm,” Abrahams said. The RBC analyst figures Biogen might consider scrapping commercialization activities and potentially the phase 4 trial to save costs.
Biogen has already revealed a cost-cutting scheme in December targeting $500 million in annual savings. And, when the CMS draft guidance came out in January, Biogen CEO Michel Vounatsos warned that he will execute “additional waves” of reshuffling to protect the company’s bottom line if the final policy stays unchanged.
In 2021, Aduhelm brought in about $3 million in sales compared with $485 million in selling, general and administrative costs. After Biogen reported those numbers, Mizuho analyst Salim Syed questioned when the company’s “fiduciary duty kicks in to shut down the program.”
Biogen's troubled Aduhelm hit with CMS slapdown—now what?
Without meaningful access for more patients, the negative Medicare policy “likely spells the end for Aduhelm,” Abrahams said. The RBC analyst figures Biogen might consider scrapping commercialization activities and potentially the phase 4 trial to save costs.
Biogen has already revealed a cost-cutting scheme in December targeting $500 million in annual savings. And, when the CMS draft guidance came out in January, Biogen CEO Michel Vounatsos warned that he will execute “additional waves” of reshuffling to protect the company’s bottom line if the final policy stays unchanged.
In 2021, Aduhelm brought in about $3 million in sales compared with $485 million in selling, general and administrative costs. After Biogen reported those numbers, Mizuho analyst Salim Syed questioned when the company’s “fiduciary duty kicks in to shut down the program.”